ClinicalTrials.gg
CompletedNCT01741792Updated Jan 6, 2017Results posted

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

A Phase 2 interventional study of Blinatumomab in Diffuse Large B-cell Lymphoma, sponsored by Amgen Research (Munich) GmbH. Completed at 6 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-06.

Sponsored by Amgen Research (Munich) GmbH (part of Amgen) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 108 studies in Lymphoma, Large B-Cell, Diffuse with a site in Germany — 15 open to participants now, 28 under way, 7 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Germany.

Enrollment
92nd of 100
25 · median 156
Started
2012
with 4 others
Phase 2
30 of 108
4 open now
Registered
40th of 108
by date

Among the 108 studies in Lymphoma, Large B-Cell, Diffuse with a site in Germany, this one is the 92nd largest by enrollment of the 100 interventional ones that give a count, is one of 5 that started in 2012, is one of 30 in phase 2, and was the 40th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

15 of the 108 studies in Lymphoma, Large B-Cell, Diffuse with a site in Germany are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Lymphoma, Large B-Cell, Diffuse with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to confirm whether the bispecific T-cell engager blinatumomab is effective and safe in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Read the detailed description

DLBCL is an aggressive malignant disease which evolves from B-cells and affects mainly the lymphatic tissue. Due to its aggressive nature the disease is characterized by a fast course which is lethal without therapy. Potentially curative therapy options are available even at advanced stages. Standard-first line leads to a high initial response rate (85-90%) and an approximate cure rate of 50% of patients. Patients refractory to or with early relapse after this treatment (10-15%) have a very poor prognosis.

Blinatumomab is a bispecific single-chain antibody derivative against CD19 and CD3, designed to link B-cells and T-cells resulting in T-cell activation and a cytotoxic T-cell response against CD19 expressing cells.

This study consisted of a screening period, treatment period, and a follow-up efficacy and survival period. The core study comprises the treatment period to the 30 days after the last infusion. The first cycle consisted of a continuous intravenous (CIV) infusion over 8 weeks. Participants who achieved a Complete Response (CR) or Partial Response (PR) or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval. After the last treatment cycle, efficacy and survival follow-up visits occurred for up to 24 months from treatment start. Participants who relapsed during the follow-up period may have received an additional 8 weeks of treatment.

Two dose regimens were assessed in this study. Stage 1 comprised 2 dose cohorts. In Cohort 1, the first 6 participants were to receive blinatumomab in a dose-escalating manner: 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. In Cohort 2, the next 6 participants enrolled were to receive a constant dose of 112 µg/day blinatumomab. Before the initiation of stage 2, a pre-planned data monitoring committee (DMC) meeting was held to assess the safety profile of Cohort 1 and Cohort 2. The dosing regimen with the more favorable benefit-risk profile was to be selected for Cohort 3.

03

Conditions studied

  • Diffuse Large B-cell Lymphoma

Keywords

  • Relapsed DLBCL
  • Refractory DLBCL
  • adult DLBCL
  • Lymphoma
  • Non-Hodgkin Lymphoma
  • Lymphatic diseases
  • Lymphoproliferative disorders
  • bispecific antibody
  • anti-CD19
  • Immunotherapeutic treatment
  • Immunoproliferative disorders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Diffuse Large B-Cell Lymphoma (DLBCL) who are to first or later treatment or have a first relapse or later relapse not eligible for hematopoietic stem cell transplant (HSCT) or relapsed post- autologous-HSCT
  • (ECOG) performance status ≤ 2
  • Age ≥ 18 years
  • of ≥ 12 weeks
  • Cerebrospinal fluid (CSF) free of infiltration by DLBCL

Exclusion criteria

Exclusion Criteria:

  • History or presence of central nervous system (CNS) pathology as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis
  • Current infiltration of CSF by DLBCL
  • History of disease with potential CNS involvement or current autoimmune disease
  • HSCT within six weeks prior to start of blinatumomab treatment
  • Prior allogeneic HSCT
  • Cancer chemotherapy within two weeks prior to start of blinatumomab treatment
  • Radiotherapy within four weeks prior to start of blinatumomab treatment
  • Immunotherapy (e.g., rituximab) within four weeks prior to start of blinatumomab treatment
  • Any anti-lymphoma product within four weeks prior to start of blinatumomab treatment
  • Treatment with any other investigational product after signature of
  • Known to immunoglobulins or to any other component of the study drug formulation
  • Abnormal laboratory values indicative of inadequate renal or liver function
  • History of other than non-Hodgkin's lymphoma (NHL) within five years prior to start of blinatumomab treatment with the exception of basal cell or squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix
  • Active uncontrolled infection, any other concurrent disease or medical condition that is deemed to interfere with the conduct of the study as judged by the investigator
  • Infection with (HIV) or chronic infection with virus or virus
  • Pregnant or nursing women
  • Previous treatment with blinatumomab
  • Presence of human anti-murine antibodies (HAMA) at screening
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Blinatumomab

    By study design, two dose regimens were assessed in this study. In Stage 1, Cohort 1, participants received blinatumomab in a dose-escalating manner: 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during cycle 1. In Cohort 2, the next participants enrolled and received a constant dose of 112 µg/day blinatumomab. The dosing regimen with the more favorable benefit-risk profile was then selected for Stage 2, Cohort 3.

    Drug: Blinatumomab

Interventions

  • Administered by continuous intravenous infusion over 8 weeks in the first cycle and 4 weeks in the second cycle.

    Also known as: AMG103, MT103, BLINCYTO®

06

What researchers measure

Primary outcomes

  1. Overall Objective Response Rate During Treatment Cycle 1

    Overall response within the first treatment cycle was assessed according to Cheson criteria by a central reader. Response was evaluated using computerized tomography (CT) scans and positron emission tomography (PET) (to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Overall objective response rate (ORR) is the percentage of participants with a best overall response of complete response (CR) or partial response (PR). Complete response is defined as the disappearance of all evidence of disease and partial response is defined as regression of measureable disease and no new sites.

    Time frame: During the first 8 weeks

Secondary outcomes

  1. Percentage of Participants With a Best Overall Response of Complete Response

    Response within the first treatment cycle was assessed according to Cheson criteria by a central reader. Response was evaluated using computerized tomography (CT) scans and positron emission tomography (PET) (to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Complete response is defined as the disappearance of all evidence of disease.

    Time frame: During the first 8 weeks

  2. Percentage of Participants With a Best Overall Response of Partial Response

    Response within the first treatment cycle was assessed according to Cheson criteria by a central reader. Response was evaluated using computerized tomography (CT) scans and positron emission tomography (PET) (to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Partial response is defined as regression (\<50% decrease in size of masses) of measureable disease and no new sites.

    Time frame: During the first 8 weeks

  3. Duration of Objective Response

    The time from documentation of the first assessment of either partial or complete response until the start of new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death, whichever is the earliest event. A patient who did not have new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death was censored at last tumor assessment date. Disease progression is defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir.

    Time frame: From first infusion of blinatumomab until the end of study; median follow-up time for duration of response was 23.7 months.

  4. Duration of Complete Response

    The time from documentation of the first assessment of complete response until the start of new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death, whichever is the earliest event. A patient who did not have new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death was censored at last tumor assessment date. Disease progression is defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir.

    Time frame: From first infusion of blinatumomab until the end of study; median follow-up time for duration of response was 23.7 months.

  5. Duration of Partial Response

    The time from documentation of the first assessment of partial response until the start of new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death, whichever is the earliest event. A patient who did not have new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death was censored at last tumor assessment date. Disease progression is defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir.

    Time frame: From first infusion of blinatumomab until the end of study; median follow-up time for duration of response was 23.7 months.

  6. Progression-free Survival (PFS)

    The time from the date of first blinatumomab infusion until the date of diagnosis of progression of lymphoma, the start date of new anti-tumor treatment (excluding any stem cell transplantation) or date of death, whichever is the earliest. Patients alive who did not have progression or new anti-tumor treatment (excluding any stem cell transplantation) were censored at last date of tumor assessment.

    Time frame: From first infusion of blinatumomab until the end of study; median time on follow-up for PFS was 27.0 months.

  7. Overall Survival (OS)

    The time from the date of first blinatumomab infusion until death as a result of any cause. Patients still alive were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive. For patients who withdrew their informed consent, only information until the date of withdrawal was analyzed.

    Time frame: From the first infusion of blinatumomab until the end of study; median time on follow-up for overall survival was 26.6 months.

  8. Number of Participants With Adverse Events

    Adverse events were evaluated for severity according to the grading scale provided in the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. An adverse event or suspected adverse drug reaction was considered "serious" if it resulted in one of the following outcomes: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant incapacity or substantial disruption to conduct normal life functions; * Was a congenital anomaly or birth defect; * Was a medically important condition. The Investigator used medical judgment to determine whether there was a causal relationship (ie, related \[reasonably possible\] or unrelated \[not reasonably possible\]) between an adverse event and blinatumomab.

    Time frame: From the first dose of blinatumomab until up to 30 days after the last dose or until the data cut-off date of 10 July 2014, whichever occurred first; the overall median duration of treatment exposure was 46.8 days.

  9. Blinatumomab Steady State Serum Concentration

    Blinatumomab serum levels were analyzed using a validated cluster of differentiation (CD)69 activation bioassay with a lower limit of quantification (LLOQ) of 50 pg/mL. Steady-state concentration (Css) was based on actual dose received, rather than based on cohort or time or day.

    Time frame: Cycle 1: predose; Day 3 and Day 8 (Css for 9 ug/day); Day 15 (Css for 28 ug/day); and Day 29, Day 43 and Day 57 (Css for 112 ug/day)

  10. Leukocyte Counts

    Leukocyte (white blood cells) counts were analyzed by differential blood count analysis.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  11. Lymphocyte Counts

    Lymphocyte counts were analyzed by differential blood count analysis.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  12. Monocyte Counts

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  13. Granulocyte Count

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  14. CD19+ B-Cell Count

    CD19+ B-cell counts were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  15. CD19+ B-Cells as a Percentage of All Lymphocytes

    CD19+ B-cell counts were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  16. CD3+ T-Cell Count

    CD3+ T-cell counts were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  17. CD3+ T-Cells as a Percentage of All Lymphocytes

    CD3+ T-cell counts were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  18. CD4+ T-Cell Count

    CD4+ T-cell counts were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  19. CD4+ T-Cells as a Percentage of All Lymphocytes

    CD4+ T-cell counts were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  20. CD8+ T-Cell Count

    CD8+ T-cell counts were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  21. CD8+ T-Cells as a Percentage of All Lymphocytes

    CD8+ T-cell counts were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  22. CD19+ B-Cell to CD3+ T-Cell Ratio

    CD19+ B-cells and CD3+ T-cell counts were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  23. CD4+ T-Cell to CD8+ T-Cell Ratio

    CD4+ T-cells and CD8+ T-cell counts were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  24. CD4+ Naive T Cell Count

    CD4+ naive T-cell counts are native T-cells characterized by the cell-surface expression of CD197 and CD45RA and were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  25. CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells

    CD4+ naive T-cell counts are native T-cells characterized by the cell-surface expression of CD197 and CD45RA and were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  26. CD4+ Central Memory T-Cell (TCM) Count

    Central memory T cells are characterized by the cell-surface expression of CD197 but not CD45RA and were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  27. CD4+ TCM Cells as a Percentage of All CD4+ T-Cells

    Central memory T cells are characterized by the cell-surface expression of CD197 but not CD45RA and were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  28. CD4+ Effector Memory T-Cell (TEM) Count

    Effector memory T cells are characterized by the lack of expression of CD197 and CD45RA and were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  29. CD4+ TEM Cells as a Percentage of All CD4+ T-Cells

    Effector memory T cells are characterized by the lack of expression of CD197 and CD45RA and were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  30. CD8+ Naive T-Cell Count

    CD8+ naive T-cell counts are native T-cells characterized by the cell-surface expression of CD197 and CD45RA and were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  31. CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells

    CD8+ naive T-cell counts are native T-cells characterized by the cell-surface expression of CD197 and CD45RA and were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  32. CD8+ TCM Cell Counts

    Central memory T cells are characterized by the cell-surface expression of CD197 but not CD45RA and were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  33. CD8+ TCM Cells as a Percentage of All CD8+ T-Cells

    Central memory T cells are characterized by the cell-surface expression of CD197 but not CD45RA and were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  34. CD8+ Effector Memory T-Cell (TEM) Count

    Effector memory T cells are characterized by the lack of expression of CD197 and CD45RA and were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  35. CD8+ TEM Cells as a Percentage of All CD8+ T-Cells

    Effector memory T cells are characterized by the lack of expression of CD197 and CD45RA and were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  36. CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count

    Terminally differentiated effector memory T cells are characterized by the cell-surface expression of CD45RA but not CD197 and were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

  37. CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells

    Terminally differentiated effector memory T cells are characterized by the cell-surface expression of CD45RA but not CD197 and were analyzed by flow cytometry.

    Time frame: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

07

Results

Posted Jul 27, 2015

Participant flow

Adults with a diagnosis of diffuse large B-cell lymphoma (DLBCL) which was refractory to first or subsequent treatment or who had a first or later relapse and were not eligible for autologous hematopoietic stem cell transplant (HSCT), or relapsed after autologous HSCT were eligible to enrol. The primary analysis cut-off date was 10 July 2014.

Participant flow — Overall Study
MilestoneCohort 1: Blinatumomab 9/28/112 µg/dCohort 2: Blinatumomab 112 µg/dCohort 3: Blinatumomab 9/28/112 µg/d
Started9214
Efficacy set7113
Completed312
Not completed6112
Withdrew: Death6112

Outcome measures

PrimaryOverall Objective Response Rate During Treatment Cycle 1

Overall response within the first treatment cycle was assessed according to Cheson criteria by a central reader. Response was evaluated using computerized tomography (CT) scans and positron emission tomography (PET) (to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Overall objective response rate (ORR) is the percentage of participants with a best overall response of complete response (CR) or partial response (PR). Complete response is defined as the disappearance of all evidence of disease and partial response is defined as regression of measureable disease and no new sites.

Time frame:
During the first 8 weeks
Reported as:
Number · percentage of participants
Overall Objective Response Rate During Treatment Cycle 1
percentage of participantsCohort 1: Blinatumomab 9/28/112 μg/dCohort 2: Blinatumomab 112 μg/dCohort 3: Blinatumomab 9/28/112 μg/d
Overall Objective Response Rate During Treatment Cycle 157.1 (18.4 to 90.1)100.0 (2.5 to 100.0)30.8 (9.1 to 61.4)
SecondaryPercentage of Participants With a Best Overall Response of Complete Response

Response within the first treatment cycle was assessed according to Cheson criteria by a central reader. Response was evaluated using computerized tomography (CT) scans and positron emission tomography (PET) (to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Complete response is defined as the disappearance of all evidence of disease.

Time frame:
During the first 8 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Overall Response of Complete Response
percentage of participantsCohort 1: Blinatumomab 9/28/112 μg/dCohort 2: Blinatumomab 112 μg/dCohort 3: Blinatumomab 9/28/112 μg/d
Percentage of Participants With a Best Overall Response of Complete Response28.6 (3.7 to 71.0)0 (0.0 to 97.5)15.4 (1.9 to 45.4)
SecondaryPercentage of Participants With a Best Overall Response of Partial Response

Response within the first treatment cycle was assessed according to Cheson criteria by a central reader. Response was evaluated using computerized tomography (CT) scans and positron emission tomography (PET) (to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Partial response is defined as regression (\<50% decrease in size of masses) of measureable disease and no new sites.

Time frame:
During the first 8 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Overall Response of Partial Response
percentage of participantsCohort 1: Blinatumomab 9/28/112 μg/dCohort 2: Blinatumomab 112 μg/dCohort 3: Blinatumomab 9/28/112 μg/d
Percentage of Participants With a Best Overall Response of Partial Response28.6 (3.7 to 71.0)100.0 (2.5 to 100.0)15.4 (1.9 to 45.4)
SecondaryDuration of Objective Response

The time from documentation of the first assessment of either partial or complete response until the start of new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death, whichever is the earliest event. A patient who did not have new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death was censored at last tumor assessment date. Disease progression is defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir.

Time frame:
From first infusion of blinatumomab until the end of study; median follow-up time for duration of response was 23.7 months.
Reported as:
Median · months
Duration of Objective Response
monthsCohort 1: Blinatumomab 9/28/112 μg/dCohort 2: Blinatumomab 112 μg/dCohort 3: Blinatumomab 9/28/112 μg/d
Duration of Objective Response8.7 (0.9 to NA)NA (NA to NA)4.0 (1.9 to NA)
SecondaryDuration of Complete Response

The time from documentation of the first assessment of complete response until the start of new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death, whichever is the earliest event. A patient who did not have new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death was censored at last tumor assessment date. Disease progression is defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir.

Time frame:
From first infusion of blinatumomab until the end of study; median follow-up time for duration of response was 23.7 months.
Reported as:
Median · months
Duration of Complete Response
monthsCohort 1: Blinatumomab 9/28/112 μg/dCohort 2: Blinatumomab 112 μg/dCohort 3: Blinatumomab 9/28/112 μg/d
Duration of Complete ResponseNA (11.6 to NA)—NA (5.9 to NA)
SecondaryDuration of Partial Response

The time from documentation of the first assessment of partial response until the start of new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death, whichever is the earliest event. A patient who did not have new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death was censored at last tumor assessment date. Disease progression is defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir.

Time frame:
From first infusion of blinatumomab until the end of study; median follow-up time for duration of response was 23.7 months.
Reported as:
Median · months
Duration of Partial Response
monthsCohort 1: Blinatumomab 9/28/112 μg/dCohort 2: Blinatumomab 112 μg/dCohort 3: Blinatumomab 9/28/112 μg/d
Duration of Partial Response3.3 (0.9 to 5.8)NA (NA to NA)2.0 (1.9 to 2.1)
SecondaryProgression-free Survival (PFS)

The time from the date of first blinatumomab infusion until the date of diagnosis of progression of lymphoma, the start date of new anti-tumor treatment (excluding any stem cell transplantation) or date of death, whichever is the earliest. Patients alive who did not have progression or new anti-tumor treatment (excluding any stem cell transplantation) were censored at last date of tumor assessment.

Time frame:
From first infusion of blinatumomab until the end of study; median time on follow-up for PFS was 27.0 months.
Reported as:
Median · months
Progression-free Survival (PFS)
monthsCohort 1: Blinatumomab 9/28/112 μg/dCohort 2: Blinatumomab 112 μg/dCohort 3: Blinatumomab 9/28/112 μg/d
Progression-free Survival (PFS)3.7 (0.7 to 14.1)NA (NA to NA)1.6 (0.6 to 4.6)
SecondaryOverall Survival (OS)

The time from the date of first blinatumomab infusion until death as a result of any cause. Patients still alive were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive. For patients who withdrew their informed consent, only information until the date of withdrawal was analyzed.

Time frame:
From the first infusion of blinatumomab until the end of study; median time on follow-up for overall survival was 26.6 months.
Reported as:
Median · months
Overall Survival (OS)
monthsCohort 1: Blinatumomab 9/28/112 μg/dCohort 2: Blinatumomab 112 μg/dCohort 3: Blinatumomab 9/28/112 μg/d
Overall Survival (OS)20.1 (2.3 to NA)NA (NA to NA)3.6 (1.5 to 14.8)
SecondaryNumber of Participants With Adverse Events

Adverse events were evaluated for severity according to the grading scale provided in the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. An adverse event or suspected adverse drug reaction was considered "serious" if it resulted in one of the following outcomes: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant incapacity or substantial disruption to conduct normal life functions; * Was a congenital anomaly or birth defect; * Was a medically important condition. The Investigator used medical judgment to determine whether there was a causal relationship (ie, related \[reasonably possible\] or unrelated \[not reasonably possible\]) between an adverse event and blinatumomab.

Time frame:
From the first dose of blinatumomab until up to 30 days after the last dose or until the data cut-off date of 10 July 2014, whichever occurred first; the overall median duration of treatment exposure was 46.8 days.
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsCohort 1: Blinatumomab 9/28/112 μg/dCohort 2: Blinatumomab 112 μg/dCohort 3: Blinatumomab 9/28/112 μg/d
Any adverse event (AE)9214
AE of Grade ≥ 39213
AE of Grade ≥ 4026
Serious adverse event (SAE)9212
Fatal adverse events002
Led to discontinuation of study drug312
Led to interruption of study drug416
Related adverse events9211
Related AE Grade ≥ 3525
Related AE Grade ≥ 4012
Serious related adverse events523
Related AE led to discontinuation of study drug212
Related AE led to interruption of study drug313
SecondaryBlinatumomab Steady State Serum Concentration

Blinatumomab serum levels were analyzed using a validated cluster of differentiation (CD)69 activation bioassay with a lower limit of quantification (LLOQ) of 50 pg/mL. Steady-state concentration (Css) was based on actual dose received, rather than based on cohort or time or day.

Time frame:
Cycle 1: predose; Day 3 and Day 8 (Css for 9 ug/day); Day 15 (Css for 28 ug/day); and Day 29, Day 43 and Day 57 (Css for 112 ug/day)
Reported as:
Mean · pg/mL
Blinatumomab Steady State Serum Concentration
pg/mLBlinatumomab 9 μg/dBlinatumomab 28 μg/dBlinatumomab 112 μg/d
Blinatumomab Steady State Serum Concentration277 ± 210565 ± 2082800 ± 1150
SecondaryLeukocyte Counts

Leukocyte (white blood cells) counts were analyzed by differential blood count analysis.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · 1000 cells/µL
Leukocyte Counts
1000 cells/µLBlinatumomab
Screening (N = 25)6.376 ± 3.284
Day 1 Prior (N = 24)5.729 ± 2.891
Day 8 (N = 21)6.819 ± 3.201
Day 15 (N = 16)6.400 ± 2.486
Day 29 (N = 11)3.764 ± 2.160
Day 43 (N = 8)4.950 ± 3.819
End of Infusion (N = 9)4.611 ± 2.114
End of Core Study (N = 6)6.850 ± 2.818
3-Month Follow-up (N = 5)4.820 ± 1.616
6-Month Follow-up (N = 6)5.183 ± 1.380
9-Month Follow-up (N = 4)4.425 ± 0.854
12-Month Follow-up (N = 4)5.700 ± 1.424
15-Month Follow-up (N = 3)4.767 ± 0.874
18-Month Follow-up (N = 3)6.467 ± 1.779
21-Month Follow-up (N = 21)5.450 ± 0.495
24-Month Follow-up (N = 3)4.533 ± 1.069
SecondaryLymphocyte Counts

Lymphocyte counts were analyzed by differential blood count analysis.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · 1000 cells/µL
Lymphocyte Counts
1000 cells/µLBlinatumomab
Screening (N = 25)0.779 ± 0.425
Day 1 Prior (N = 24)0.491 ± 0.259
Day 8 (N = 21)0.382 ± 0.215
Day 15 (N = 16)0.277 ± 0.165
Day 29 (N = 11)0.472 ± 0.273
Day 43 (N = 8)0.847 ± 0.511
End of Infusion (N = 9)0.767 ± 0.505
End of Core Study (N = 6)1.060 ± 0.489
3-Month Follow-up (N = 5)1.053 ± 0.421
6-Month Follow-up (N = 6)1.120 ± 0.621
9-Month Follow-up (N = 4)1.048 ± 0.381
12-Month Follow-up (N = 4)1.120 ± 0.449
15-Month Follow-up (N = 3)0.998 ± 0.527
18-Month Follow-up (N = 3)0.565 ± 0.180
21-Month Follow-up (N = 21)1.205 ± 0.839
24-Month Follow-up (N = 3)0.737 ± 0.478
SecondaryMonocyte Counts
Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · 1000 cells/µL
Monocyte Counts
1000 cells/µLBlinatumomab
Screening (N = 25)0.638 ± 0.415
Day 1 Prior (N = 24)0.300 ± 0.565
Day 8 (N = 21)0.202 ± 0.386
Day 15 (N = 16)0.188 ± 0.317
Day 29 (N = 11)0.318 ± 0.185
Day 43 (N = 8)0.646 ± 0.375
End of Infusion (N = 9)0.473 ± 0.241
End of Core Study (N = 6)0.711 ± 0.569
3-Month Follow-up (N = 5)0.585 ± 0.280
6-Month Follow-up (N = 6)0.487 ± 0.239
9-Month Follow-up (N = 4)0.452 ± 0.112
12-Month Follow-up (N = 4)0.469 ± 0.061
15-Month Follow-up (N = 3)0.511 ± 0.053
18-Month Follow-up (N = 3)0.290 ± 0.123
21-Month Follow-up (N = 21)0.516 ± 0.008
24-Month Follow-up (N = 3)0.234 ± 0.176
SecondaryGranulocyte Count
Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · 1000 cells/µL
Granulocyte Count
1000 cells/µLBlinatumomab
Screening (N = 25)4.968 ± 3.187
Day 1 Prior (N = 24)4.910 ± 2.425
Day 8 (N = 21)6.235 ± 2.881
Day 15 (N = 16)5.935 ± 2.387
Day 29 (N = 11)2.974 ± 2.019
Day 43 (N = 8)3.457 ± 3.395
End of Infusion (N = 9)3.353 ± 2.134
End of Core Study (N = 6)5.080 ± 3.012
3-Month Follow-up (N = 5)3.182 ± 1.117
6-Month Follow-up (N = 6)3.594 ± 0.950
9-Month Follow-up (N = 4)2.925 ± 0.675
12-Month Follow-up (N = 4)4.111 ± 1.382
15-Month Follow-up (N = 3)3.258 ± 0.745
18-Month Follow-up (N = 3)5.612 ± 1.713
21-Month Follow-up (N = 21)3.729 ± 0.352
24-Month Follow-up (N = 3)3.563 ± 0.711
SecondaryCD19+ B-Cell Count

CD19+ B-cell counts were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · 1000 cells/µL
CD19+ B-Cell Count
1000 cells/µLBlinatumomab
Screening (N = 25)0.026 ± 0.072
Day 1 Prior (N = 24)0.029 ± 0.085
Day 8 (N = 21)0.001 ± 0.002
Day 15 (N = 16)0.000 ± 0.001
Day 29 (N = 11)0.000 ± 0.000
Day 43 (N = 8)0.000 ± 0.001
End of Infusion (N = 9)0.001 ± 0.001
End of Core Study (N = 6)0.001 ± 0.002
3-Month Follow-up (N = 5)0.025 ± 0.026
6-Month Follow-up (N = 6)0.029 ± 0.043
9-Month Follow-up (N = 4)0.054 ± 0.066
12-Month Follow-up (N = 4)0.082 ± 0.113
15-Month Follow-up (N = 3)0.094 ± 0.118
18-Month Follow-up (N = 3)0.071 ± 0.075
21-Month Follow-up (N = 21)0.131 ± 0.170
24-Month Follow-up (N = 3)0.108 ± 0.120
SecondaryCD19+ B-Cells as a Percentage of All Lymphocytes

CD19+ B-cell counts were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · percentage of lymphocytes
CD19+ B-Cells as a Percentage of All Lymphocytes
percentage of lymphocytesBlinatumomab
Screening (N = 25)2 ± 7
Day 1 Prior (N = 24)4 ± 9
Day 8 (N = 21)0 ± 0
Day 15 (N = 16)0 ± 0
Day 29 (N = 11)0 ± 0
Day 43 (N = 8)0 ± 0
End of Infusion (N = 9)0 ± 0
End of Core Study (N = 6)0 ± 0
3-Month Follow-up (N = 5)2 ± 2
6-Month Follow-up (N = 6)2 ± 3
9-Month Follow-up (N = 4)5 ± 5
12-Month Follow-up (N = 4)7 ± 9
15-Month Follow-up (N = 3)7 ± 7
18-Month Follow-up (N = 3)11 ± 9
21-Month Follow-up (N = 21)8 ± 8
24-Month Follow-up (N = 3)12 ± 7
SecondaryCD3+ T-Cell Count

CD3+ T-cell counts were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · 1000 cells/µL
CD3+ T-Cell Count
1000 cells/µLBlinatumomab
Screening (N = 25)0.578 ± 0.355
Day 1 Prior (N = 24)0.349 ± 0.233
Day 8 (N = 21)0.282 ± 0.194
Day 15 (N = 16)0.199 ± 0.159
Day 29 (N = 11)0.348 ± 0.231
Day 43 (N = 8)0.613 ± 0.426
End of Infusion (N = 9)0.543 ± 0.421
End of Core Study (N = 6)0.825 ± 0.431
3-Month Follow-up (N = 5)0.773 ± 0.443
6-Month Follow-up (N = 6)0.782 ± 0.345
9-Month Follow-up (N = 4)0.671 ± 0.184
12-Month Follow-up (N = 4)0.703 ± 0.203
15-Month Follow-up (N = 3)0.594 ± 0.227
18-Month Follow-up (N = 3)0.298 ± 0.049
21-Month Follow-up (N = 21)0.623 ± 0.266
24-Month Follow-up (N = 3)0.456 ± 0.257
SecondaryCD3+ T-Cells as a Percentage of All Lymphocytes

CD3+ T-cell counts were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · percentage of lymphocytes
CD3+ T-Cells as a Percentage of All Lymphocytes
percentage of lymphocytesBlinatumomab
Screening (N = 25)72 ± 14
Day 1 Prior (N = 24)68 ± 18
Day 8 (N = 21)70 ± 19
Day 15 (N = 16)67 ± 19
Day 29 (N = 11)73 ± 15
Day 43 (N = 8)71 ± 13
End of Infusion (N = 9)66 ± 14
End of Core Study (N = 6)76 ± 16
3-Month Follow-up (N = 5)73 ± 11
6-Month Follow-up (N = 6)66 ± 21
9-Month Follow-up (N = 4)66 ± 6
12-Month Follow-up (N = 4)65 ± 9
15-Month Follow-up (N = 3)61 ± 7
18-Month Follow-up (N = 3)57 ± 20
21-Month Follow-up (N = 21)58 ± 16
24-Month Follow-up (N = 3)63 ± 8
SecondaryCD4+ T-Cell Count

CD4+ T-cell counts were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · 1000 cells/µL
CD4+ T-Cell Count
1000 cells/µLBlinatumomab
Screening (N = 25)0.254 ± 0.160
Day 1 Prior (N = 24)0.152 ± 0.128
Day 8 (N = 21)0.131 ± 0.128
Day 15 (N = 16)0.085 ± 0.084
Day 29 (N = 11)0.170 ± 0.172
Day 43 (N = 8)0.261 ± 0.219
End of Infusion (N = 9)0.241 ± 0.254
End of Core Study (N = 6)0.375 ± 0.251
3-Month Follow-up (N = 5)0.371 ± 0.216
6-Month Follow-up (N = 6)0.371 ± 0.237
9-Month Follow-up (N = 4)0.309 ± 0.184
12-Month Follow-up (N = 4)0.399 ± 0.193
15-Month Follow-up (N = 3)0.326 ± 0.220
18-Month Follow-up (N = 3)0.178 ± 0.042
21-Month Follow-up (N = 21)0.373 ± 0.279
24-Month Follow-up (N = 3)0.258 ± 0.248
SecondaryCD4+ T-Cells as a Percentage of All Lymphocytes

CD4+ T-cell counts were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · percentage of lymphocytes
CD4+ T-Cells as a Percentage of All Lymphocytes
percentage of lymphocytesBlinatumomab
Screening (N = 25)33 ± 11
Day 1 Prior (N = 24)28 ± 14
Day 8 (N = 21)32 ± 17
Day 15 (N = 16)29 ± 13
Day 29 (N = 11)34 ± 18
Day 43 (N = 8)30 ± 12
End of Infusion (N = 9)28 ± 13
End of Core Study (N = 6)32 ± 15
3-Month Follow-up (N = 5)33 ± 9
6-Month Follow-up (N = 6)30 ± 10
9-Month Follow-up (N = 4)31 ± 13
12-Month Follow-up (N = 4)35 ± 7
15-Month Follow-up (N = 3)31 ± 7
18-Month Follow-up (N = 3)32 ± 6
21-Month Follow-up (N = 21)29 ± 4
24-Month Follow-up (N = 3)34 ± 8
SecondaryCD8+ T-Cell Count

CD8+ T-cell counts were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · 1000 cells/µL
CD8+ T-Cell Count
1000 cells/µLBlinatumomab
Screening (N = 25)0.298 ± 0.256
Day 1 Prior (N = 24)0.186 ± 0.136
Day 8 (N = 21)0.134 ± 0.099
Day 15 (N = 16)0.102 ± 0.095
Day 29 (N = 11)0.140 ± 0.076
Day 43 (N = 8)0.299 ± 0.237
End of Infusion (N = 9)0.284 ± 0.195
End of Core Study (N = 6)0.438 ± 0.284
3-Month Follow-up (N = 5)0.381 ± 0.254
6-Month Follow-up (N = 6)0.403 ± 0.304
9-Month Follow-up (N = 4)0.225 ± 0.039
12-Month Follow-up (N = 4)0.310 ± 0.200
15-Month Follow-up (N = 3)0.214 ± 0.023
18-Month Follow-up (N = 3)0.105 ± 0.057
21-Month Follow-up (N = 21)0.185 ± 0.026
24-Month Follow-up (N = 3)0.187 ± 0.068
SecondaryCD8+ T-Cells as a Percentage of All Lymphocytes

CD8+ T-cell counts were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · percentage of lymphocytes
CD8+ T-Cells as a Percentage of All Lymphocytes
percentage of lymphocytesBlinatumomab
Screening (N = 25)37 ± 18
Day 1 Prior (N = 24)37 ± 19
Day 8 (N = 21)35 ± 19
Day 15 (N = 16)35 ± 17
Day 29 (N = 11)33 ± 17
Day 43 (N = 8)37 ± 15
End of Infusion (N = 9)36 ± 16
End of Core Study (N = 6)43 ± 23
3-Month Follow-up (N = 5)36 ± 19
6-Month Follow-up (N = 6)34 ± 16
9-Month Follow-up (N = 4)25 ± 11
12-Month Follow-up (N = 4)28 ± 13
15-Month Follow-up (N = 3)24 ± 9
18-Month Follow-up (N = 3)21 ± 13
21-Month Follow-up (N = 21)20 ± 12
24-Month Follow-up (N = 3)27 ± 16
SecondaryCD19+ B-Cell to CD3+ T-Cell Ratio

CD19+ B-cells and CD3+ T-cell counts were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · ratio
CD19+ B-Cell to CD3+ T-Cell Ratio
ratioBlinatumomab
Screening (N = 25)0.04 ± 0.15
Day 1 Prior (N = 24)0.07 ± 0.24
Day 8 (N = 21)0.00 ± 0.01
Day 15 (N = 16)0.00 ± 0.00
Day 29 (N = 11)0.00 ± 0.00
Day 43 (N = 8)0.00 ± 0.00
End of Infusion (N = 9)0.00 ± 0.01
End of Core Study (N = 6)0.00 ± 0.00
3-Month Follow-up (N = 5)0.03 ± 0.03
6-Month Follow-up (N = 6)0.04 ± 0.05
9-Month Follow-up (N = 4)0.08 ± 0.08
12-Month Follow-up (N = 4)0.12 ± 0.15
15-Month Follow-up (N = 3)0.13 ± 0.13
18-Month Follow-up (N = 3)0.25 ± 0.30
21-Month Follow-up (N = 21)0.17 ± 0.20
24-Month Follow-up (N = 3)0.19 ± 0.13
SecondaryCD4+ T-Cell to CD8+ T-Cell Ratio

CD4+ T-cells and CD8+ T-cell counts were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · ratio
CD4+ T-Cell to CD8+ T-Cell Ratio
ratioBlinatumomab
Screening (N = 25)1.32 ± 1.19
Day 1 Prior (N = 24)1.16 ± 1.45
Day 8 (N = 21)1.20 ± 0.96
Day 15 (N = 16)1.03 ± 0.71
Day 29 (N = 11)1.43 ± 1.08
Day 43 (N = 8)0.96 ± 0.53
End of Infusion (N = 9)1.09 ± 1.00
End of Core Study (N = 6)1.03 ± 0.80
3-Month Follow-up (N = 5)1.18 ± 0.79
6-Month Follow-up (N = 6)1.10 ± 0.70
9-Month Follow-up (N = 4)1.53 ± 1.25
12-Month Follow-up (N = 4)1.70 ± 1.47
15-Month Follow-up (N = 3)1.47 ± 0.81
18-Month Follow-up (N = 3)2.23 ± 1.70
21-Month Follow-up (N = 21)1.85 ± 1.34
24-Month Follow-up (N = 3)1.73 ± 1.21
SecondaryCD4+ Naive T Cell Count

CD4+ naive T-cell counts are native T-cells characterized by the cell-surface expression of CD197 and CD45RA and were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · 1000 cells/µL
CD4+ Naive T Cell Count
1000 cells/µLBlinatumomab
Screening (N = 25)0.028 ± 0.056
Day 1 Prior (N = 24)0.013 ± 0.022
Day 8 (N = 21)0.014 ± 0.033
Day 15 (N = 16)0.012 ± 0.024
Day 29 (N = 11)0.032 ± 0.071
Day 43 (N = 8)0.036 ± 0.060
End of Infusion (N = 9)0.037 ± 0.088
End of Core Study (N = 6)0.050 ± 0.083
3-Month Follow-up (N = 5)0.015 ± 0.019
6-Month Follow-up (N = 6)0.023 ± 0.044
9-Month Follow-up (N = 4)0.053 ± 0.090
12-Month Follow-up (N = 4)0.053 ± 0.084
15-Month Follow-up (N = 3)0.044 ± 0.059
18-Month Follow-up (N = 3)0.035 ± 0.041
21-Month Follow-up (N = 21)0.098 ± 0.103
24-Month Follow-up (N = 3)0.016 ± 0.013
SecondaryCD4+ Naive T Cells as a Percentage of All CD4+ T-Cells

CD4+ naive T-cell counts are native T-cells characterized by the cell-surface expression of CD197 and CD45RA and were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · percentage of CD4+ T-cells
CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells
percentage of CD4+ T-cellsBlinatumomab
Screening (N = 25)8 ± 9
Day 1 Prior (N = 24)7 ± 7
Day 8 (N = 21)7 ± 7
Day 15 (N = 16)10 ± 9
Day 29 (N = 11)9 ± 11
Day 43 (N = 8)10 ± 10
End of Infusion (N = 9)8 ± 9
End of Core Study (N = 6)9 ± 13
3-Month Follow-up (N = 5)4 ± 3
6-Month Follow-up (N = 6)4 ± 7
9-Month Follow-up (N = 4)11 ± 15
12-Month Follow-up (N = 4)12 ± 14
15-Month Follow-up (N = 3)10 ± 9
18-Month Follow-up (N = 3)19 ± 19
21-Month Follow-up (N = 21)23 ± 9
24-Month Follow-up (N = 3)8 ± 10
SecondaryCD4+ Central Memory T-Cell (TCM) Count

Central memory T cells are characterized by the cell-surface expression of CD197 but not CD45RA and were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · 1000 cells/µL
CD4+ Central Memory T-Cell (TCM) Count
1000 cells/µLBlinatumomab
Screening (N = 25)0.048 ± 0.053
Day 1 Prior (N = 24)0.029 ± 0.034
Day 8 (N = 21)0.027 ± 0.042
Day 15 (N = 16)0.014 ± 0.025
Day 29 (N = 11)0.032 ± 0.065
Day 43 (N = 8)0.032 ± 0.035
End of Infusion (N = 9)0.049 ± 0.103
End of Core Study (N = 6)0.062 ± 0.075
3-Month Follow-up (N = 5)0.019 ± 0.009
6-Month Follow-up (N = 6)0.027 ± 0.020
9-Month Follow-up (N = 4)0.043 ± 0.056
12-Month Follow-up (N = 4)0.065 ± 0.073
15-Month Follow-up (N = 3)0.039 ± 0.020
18-Month Follow-up (N = 3)0.033 ± 0.031
21-Month Follow-up (N = 21)0.056 ± 0.054
24-Month Follow-up (N = 3)0.021 ± 0.010
SecondaryCD4+ TCM Cells as a Percentage of All CD4+ T-Cells

Central memory T cells are characterized by the cell-surface expression of CD197 but not CD45RA and were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · percentage of CD4+ T-cells
CD4+ TCM Cells as a Percentage of All CD4+ T-Cells
percentage of CD4+ T-cellsBlinatumomab
Screening (N = 25)18 ± 12
Day 1 Prior (N = 24)20 ± 15
Day 8 (N = 21)19 ± 15
Day 15 (N = 16)14 ± 12
Day 29 (N = 11)13 ± 10
Day 43 (N = 8)13 ± 9
End of Infusion (N = 9)15 ± 11
End of Core Study (N = 6)14 ± 11
3-Month Follow-up (N = 5)6 ± 3
6-Month Follow-up (N = 6)9 ± 4
9-Month Follow-up (N = 4)11 ± 9
12-Month Follow-up (N = 4)18 ± 16
15-Month Follow-up (N = 3)13 ± 6
18-Month Follow-up (N = 3)18 ± 14
21-Month Follow-up (N = 21)14 ± 4
24-Month Follow-up (N = 3)12 ± 11
SecondaryCD4+ Effector Memory T-Cell (TEM) Count

Effector memory T cells are characterized by the lack of expression of CD197 and CD45RA and were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · 1000 cells/µL
CD4+ Effector Memory T-Cell (TEM) Count
1000 cells/µLBlinatumomab
Screening (N = 25)0.161 ± 0.089
Day 1 Prior (N = 24)0.099 ± 0.096
Day 8 (N = 21)0.083 ± 0.076
Day 15 (N = 16)0.051 ± 0.044
Day 29 (N = 11)0.097 ± 0.059
Day 43 (N = 8)0.169 ± 0.117
End of Infusion (N = 9)0.140 ± 0.091
End of Core Study (N = 6)0.220 ± 0.142
3-Month Follow-up (N = 5)0.279 ± 0.153
6-Month Follow-up (N = 6)0.267 ± 0.158
9-Month Follow-up (N = 4)0.191 ± 0.037
12-Month Follow-up (N = 4)0.226 ± 0.100
15-Month Follow-up (N = 3)0.199 ± 0.087
18-Month Follow-up (N = 3)0.106 ± 0.066
21-Month Follow-up (N = 21)0.181 ± 0.107
24-Month Follow-up (N = 3)0.175 ± 0.133
SecondaryCD4+ TEM Cells as a Percentage of All CD4+ T-Cells

Effector memory T cells are characterized by the lack of expression of CD197 and CD45RA and were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · percentage of CD4+ T-cells
CD4+ TEM Cells as a Percentage of All CD4+ T-Cells
percentage of CD4+ T-cellsBlinatumomab
Screening (N = 25)41 ± 19
Day 1 Prior (N = 24)39 ± 19
Day 8 (N = 21)36 ± 19
Day 15 (N = 16)46 ± 17
Day 29 (N = 11)34 ± 20
Day 43 (N = 8)39 ± 26
End of Infusion (N = 9)41 ± 24
End of Core Study (N = 6)41 ± 24
3-Month Follow-up (N = 5)46 ± 26
6-Month Follow-up (N = 6)41 ± 21
9-Month Follow-up (N = 4)42 ± 18
12-Month Follow-up (N = 4)40 ± 15
15-Month Follow-up (N = 3)46 ± 17
18-Month Follow-up (N = 3)43 ± 12
21-Month Follow-up (N = 21)45 ± 3
24-Month Follow-up (N = 3)51 ± 22
SecondaryCD8+ Naive T-Cell Count

CD8+ naive T-cell counts are native T-cells characterized by the cell-surface expression of CD197 and CD45RA and were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · 1000 cells/µL
CD8+ Naive T-Cell Count
1000 cells/µLBlinatumomab
Screening (N = 25)0.029 ± 0.043
Day 1 Prior (N = 24)0.024 ± 0.050
Day 8 (N = 21)0.010 ± 0.012
Day 15 (N = 16)0.006 ± 0.005
Day 29 (N = 11)0.012 ± 0.014
Day 43 (N = 8)0.019 ± 0.036
End of Infusion (N = 9)0.011 ± 0.015
End of Core Study (N = 6)0.023 ± 0.018
3-Month Follow-up (N = 5)0.011 ± 0.007
6-Month Follow-up (N = 6)0.020 ± 0.022
9-Month Follow-up (N = 4)0.011 ± 0.012
12-Month Follow-up (N = 4)0.011 ± 0.009
15-Month Follow-up (N = 3)0.014 ± 0.011
18-Month Follow-up (N = 3)0.007 ± 0.008
21-Month Follow-up (N = 21)0.015 ± 0.006
24-Month Follow-up (N = 3)0.010 ± 0.009
SecondaryCD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells

CD8+ naive T-cell counts are native T-cells characterized by the cell-surface expression of CD197 and CD45RA and were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · percentage of CD8+ T-cells
CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells
percentage of CD8+ T-cellsBlinatumomab
Screening (N = 25)10 ± 10
Day 1 Prior (N = 24)12 ± 13
Day 8 (N = 21)9 ± 8
Day 15 (N = 16)8 ± 7
Day 29 (N = 11)8 ± 7
Day 43 (N = 8)6 ± 7
End of Infusion (N = 9)3 ± 3
End of Core Study (N = 6)6 ± 6
3-Month Follow-up (N = 5)4 ± 4
6-Month Follow-up (N = 6)5 ± 5
9-Month Follow-up (N = 4)6 ± 7
12-Month Follow-up (N = 4)6 ± 6
15-Month Follow-up (N = 3)6 ± 5
18-Month Follow-up (N = 3)10 ± 8
21-Month Follow-up (N = 21)8 ± 4
24-Month Follow-up (N = 3)10 ± 12
SecondaryCD8+ TCM Cell Counts

Central memory T cells are characterized by the cell-surface expression of CD197 but not CD45RA and were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · 100 cells/µL
CD8+ TCM Cell Counts
100 cells/µLBlinatumomab
Screening (N = 25)0.020 ± 0.027
Day 1 Prior (N = 24)0.014 ± 0.021
Day 8 (N = 21)0.010 ± 0.013
Day 15 (N = 16)0.004 ± 0.005
Day 29 (N = 11)0.007 ± 0.007
Day 43 (N = 8)0.012 ± 0.015
End of Infusion (N = 9)0.009 ± 0.009
End of Core Study (N = 6)0.016 ± 0.023
3-Month Follow-up (N = 5)0.008 ± 0.003
6-Month Follow-up (N = 6)0.016 ± 0.014
9-Month Follow-up (N = 4)0.006 ± 0.004
12-Month Follow-up (N = 4)0.010 ± 0.010
15-Month Follow-up (N = 3)0.004 ± 0.002
18-Month Follow-up (N = 3)0.002 ± 0.001
21-Month Follow-up (N = 21)0.002 ± 0.001
24-Month Follow-up (N = 3)0.006 ± 0.004
SecondaryCD8+ TCM Cells as a Percentage of All CD8+ T-Cells

Central memory T cells are characterized by the cell-surface expression of CD197 but not CD45RA and were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · percentage of CD8+ T-cells
CD8+ TCM Cells as a Percentage of All CD8+ T-Cells
percentage of CD8+ T-cellsBlinatumomab
Screening (N = 25)7 ± 7
Day 1 Prior (N = 24)8 ± 11
Day 8 (N = 21)10 ± 13
Day 15 (N = 16)4 ± 5
Day 29 (N = 11)7 ± 10
Day 43 (N = 8)9 ± 18
End of Infusion (N = 9)5 ± 6
End of Core Study (N = 6)5 ± 8
3-Month Follow-up (N = 5)3 ± 2
6-Month Follow-up (N = 6)4 ± 3
9-Month Follow-up (N = 4)3 ± 2
12-Month Follow-up (N = 4)3 ± 3
15-Month Follow-up (N = 3)2 ± 1
18-Month Follow-up (N = 3)2 ± 1
21-Month Follow-up (N = 21)1 ± 0
24-Month Follow-up (N = 3)6 ± 8
SecondaryCD8+ Effector Memory T-Cell (TEM) Count

Effector memory T cells are characterized by the lack of expression of CD197 and CD45RA and were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · 1000 cells/µL
CD8+ Effector Memory T-Cell (TEM) Count
1000 cells/µLBlinatumomab
Screening (N = 25)0.127 ± 0.162
Day 1 Prior (N = 24)0.075 ± 0.066
Day 8 (N = 21)0.065 ± 0.058
Day 15 (N = 16)0.045 ± 0.053
Day 29 (N = 11)0.067 ± 0.039
Day 43 (N = 8)0.135 ± 0.108
End of Infusion (N = 9)0.128 ± 0.077
End of Core Study (N = 6)0.180 ± 0.089
3-Month Follow-up (N = 5)0.146 ± 0.071
6-Month Follow-up (N = 6)0.179 ± 0.158
9-Month Follow-up (N = 4)0.116 ± 0.061
12-Month Follow-up (N = 4)0.174 ± 0.162
15-Month Follow-up (N = 3)0.095 ± 0.025
18-Month Follow-up (N = 3)0.049 ± 0.027
21-Month Follow-up (N = 21)0.085 ± 0.013
24-Month Follow-up (N = 3)0.054 ± 0.027
SecondaryCD8+ TEM Cells as a Percentage of All CD8+ T-Cells

Effector memory T cells are characterized by the lack of expression of CD197 and CD45RA and were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · percentage of CD8+ T-cells
CD8+ TEM Cells as a Percentage of All CD8+ T-Cells
percentage of CD8+ T-cellsBlinatumomab
Screening (N = 25)42 ± 19
Day 1 Prior (N = 24)42 ± 17
Day 8 (N = 21)46 ± 18
Day 15 (N = 16)43 ± 13
Day 29 (N = 11)51 ± 19
Day 43 (N = 8)46 ± 23
End of Infusion (N = 9)51 ± 21
End of Core Study (N = 6)49 ± 22
3-Month Follow-up (N = 5)47 ± 23
6-Month Follow-up (N = 6)50 ± 24
9-Month Follow-up (N = 4)50 ± 21
12-Month Follow-up (N = 4)51 ± 13
15-Month Follow-up (N = 3)46 ± 15
18-Month Follow-up (N = 3)46 ± 7
21-Month Follow-up (N = 21)46 ± 1
24-Month Follow-up (N = 3)33 ± 9
SecondaryCD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count

Terminally differentiated effector memory T cells are characterized by the cell-surface expression of CD45RA but not CD197 and were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · 1000 cells/µL
CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count
1000 cells/µLBlinatumomab
Screening (N = 25)0.123 ± 0.099
Day 1 Prior (N = 24)0.072 ± 0.069
Day 8 (N = 21)0.051 ± 0.042
Day 15 (N = 16)0.047 ± 0.048
Day 29 (N = 11)0.058 ± 0.050
Day 43 (N = 8)0.132 ± 0.126
End of Infusion (N = 9)0.135 ± 0.131
End of Core Study (N = 6)0.226 ± 0.249
3-Month Follow-up (N = 5)0.214 ± 0.220
6-Month Follow-up (N = 6)0.187 ± 0.182
9-Month Follow-up (N = 4)0.094 ± 0.046
12-Month Follow-up (N = 4)0.117 ± 0.065
15-Month Follow-up (N = 3)0.099 ± 0.041
18-Month Follow-up (N = 3)0.047 ± 0.035
21-Month Follow-up (N = 21)0.086 ± 0.016
24-Month Follow-up (N = 3)0.100 ± 0.084
SecondaryCD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells

Terminally differentiated effector memory T cells are characterized by the cell-surface expression of CD45RA but not CD197 and were analyzed by flow cytometry.

Time frame:
Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment
Reported as:
Mean · percentage of CD8+ T-cells
CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells
percentage of CD8+ T-cellsBlinatumomab
Screening (N = 25)41 ± 19
Day 1 Prior (N = 24)39 ± 19
Day 8 (N = 21)36 ± 19
Day 15 (N = 16)46 ± 17
Day 29 (N = 11)34 ± 20
Day 43 (N = 8)39 ± 26
End of Infusion (N = 9)41 ± 24
End of Core Study (N = 6)41 ± 24
3-Month Follow-up (N = 5)46 ± 26
6-Month Follow-up (N = 6)41 ± 21
9-Month Follow-up (N = 4)42 ± 18
12-Month Follow-up (N = 4)40 ± 15
15-Month Follow-up (N = 3)46 ± 17
18-Month Follow-up (N = 3)43 ± 12
21-Month Follow-up (N = 21)45 ± 3
24-Month Follow-up (N = 3)51 ± 22

Adverse events

Collected over From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Blinatumomab 9/28/112 µg/d—9/9 (100%)9/9 (100%)
Cohort 2: Blinatumomab 112 µg/d—2/2 (100%)2/2 (100%)
Cohort 3: Blinatumomab 9/28/112 µg/d—12/14 (85.7%)14/14 (100%)
Cohort 1+3: Blinatumomab 9/28/112µg/d—21/23 (91.3%)23/23 (100%)
Blinatumomab Overall—23/25 (92%)25/25 (100%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventCohort 1: Blinatumomab 9/28/112 µg/dCohort 2: Blinatumomab 112 µg/dCohort 3: Blinatumomab 9/28/112 µg/dCohort 1+3: Blinatumomab 9/28/112µg/dBlinatumomab Overall
AgranulocytosisBlood and lymphatic system disorders0/91/20/140/231/25
Bone marrow toxicityBlood and lymphatic system disorders0/91/20/140/231/25
NeutropeniaBlood and lymphatic system disorders0/91/20/140/231/25
PyrexiaGeneral disorders1/91/22/143/234/25
PneumoniaInfections and infestations3/91/22/145/236/25
Drug administration errorInjury, poisoning and procedural complications0/91/20/140/231/25
EpilepsyNervous system disorders0/91/20/140/231/25
Neurological symptomNervous system disorders1/91/20/141/232/25
Speech disorderNervous system disorders1/91/20/141/232/25
Respiratory failureRespiratory, thoracic and mediastinal disorders0/91/20/140/231/25
Most frequent other events
Showing 10 of 144
Most frequent other events
EventCohort 1: Blinatumomab 9/28/112 µg/dCohort 2: Blinatumomab 112 µg/dCohort 3: Blinatumomab 9/28/112 µg/dCohort 1+3: Blinatumomab 9/28/112µg/dBlinatumomab Overall
TremorNervous system disorders6/92/24/1410/2312/25
AnaemiaBlood and lymphatic system disorders0/91/21/141/232/25
ArrhythmiaCardiac disorders0/91/20/140/231/25
DiarrhoeaGastrointestinal disorders4/91/21/145/236/25
FatigueGeneral disorders3/91/23/146/237/25
PyrexiaGeneral disorders4/91/25/149/2310/25
Drug hypersensitivityImmune system disorders1/91/20/141/232/25
Fungal infectionInfections and infestations1/91/20/141/232/25
Platelet count decreasedInvestigations0/91/21/141/232/25
White blood cell count decreasedInvestigations0/91/21/141/232/25

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1: Blinatumomab 9/28/112 µg/dCohort 2: Blinatumomab 112 µg/dCohort 3: Blinatumomab 9/28/112 µg/dTotal
Mean71.7 ± 7.864.5 ± 13.457.1 ± 13.662.9 ± 13.3
Gender
Gender(Participants)Cohort 1: Blinatumomab 9/28/112 µg/dCohort 2: Blinatumomab 112 µg/dCohort 3: Blinatumomab 9/28/112 µg/dTotal
Female70411
Male221014
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Cohort 1: Blinatumomab 9/28/112 µg/dCohort 2: Blinatumomab 112 µg/dCohort 3: Blinatumomab 9/28/112 µg/dTotal
White921425
Relapsed/refractory Status to Last Prior Treatment
Relapsed/refractory Status to Last Prior Treatment(participants)Cohort 1: Blinatumomab 9/28/112 µg/dCohort 2: Blinatumomab 112 µg/dCohort 3: Blinatumomab 9/28/112 µg/dTotal
Relapsed4149
Refractory511016
Number of Previous Autologous Hematopoietic Stem Cell Transplants (HSCT)
Number of Previous Autologous Hematopoietic Stem Cell Transplants (HSCT)(participants)Cohort 1: Blinatumomab 9/28/112 µg/dCohort 2: Blinatumomab 112 µg/dCohort 3: Blinatumomab 9/28/112 µg/dTotal
None711018
≥ 12147
08

Study locations

6 sites
  • Universitätsmedizin
    Göttingen, Germany
  • Universitätsklinikum des Saarlandes
    Homburg, Germany
  • Universitätsklinikum Schleswig Holstein
    Kiel, Germany
  • Klinikum der Johannes-Gutenberg Universität
    Mainz, Germany
  • Universitätsklinikum
    Ulm, Germany
  • Universititätsklinikum
    Würzburg, Germany
09

References and documents

Publications

  • Zhu M, Wu B, Brandl C, Johnson J, Wolf A, Chow A, Doshi S. Blinatumomab, a Bispecific T-cell Engager (BiTE((R))) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications. Clin Pharmacokinet. 2016 Oct;55(10):1271-1288. doi: 10.1007/s40262-016-0405-4. PubMed 27209293 ↗
  • Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, Zettl F, Libicher M, Sayehli C, Stieglmaier J, Zhang A, Nagorsen D, Bargou RC. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016 Mar 17;127(11):1410-6. doi: 10.1182/blood-2015-06-651380. Epub 2016 Jan 11. PubMed 26755709 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Jul 2014 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2012
First posted
Dec 5, 2012
Start
Jul 2012
Primary completionActual
Jul 2014
CompletionActual
Sep 2015
Results first posted
Jul 27, 2015
Last update
Jan 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01741792
Responsible party
Sponsor
First posted
Dec 5, 2012
Start date
Jul 2012
Primary completion
Jul 2014
Completion
Sep 2015
Results posted
Jul 27, 2015
Last update
Jan 6, 2017

Study contacts

- MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion